EA201991341A1 - Фенитоин для местного применения для лечения периферической нейропатической боли - Google Patents

Фенитоин для местного применения для лечения периферической нейропатической боли

Info

Publication number
EA201991341A1
EA201991341A1 EA201991341A EA201991341A EA201991341A1 EA 201991341 A1 EA201991341 A1 EA 201991341A1 EA 201991341 A EA201991341 A EA 201991341A EA 201991341 A EA201991341 A EA 201991341A EA 201991341 A1 EA201991341 A1 EA 201991341A1
Authority
EA
Eurasian Patent Office
Prior art keywords
phenytoin
neuropathic pain
peripheral neuropathic
neuropathies
treatment
Prior art date
Application number
EA201991341A
Other languages
English (en)
Inventor
Ян Мариус Кеппел Хесселинк
Давид Йос Копски
Original Assignee
Топикал Инновэйшнс Б.В.
Ян Мариус Кеппел Хесселинк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Топикал Инновэйшнс Б.В., Ян Мариус Кеппел Хесселинк filed Critical Топикал Инновэйшнс Б.В.
Publication of EA201991341A1 publication Critical patent/EA201991341A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к фармацевтическим композициям, содержащим фенитоин или фенитоин натрия, для применения при местном обезболивании. Указанное применение фармацевтической композиции изобретения уменьшает периферическую нейропатическую боль. Неожиданно было обнаружено, что фармацевтические композиции для местного применения в соответствии с изобретением, содержащие фенитоин или фенитоин натрия, существенно уменьшают периферическую нейропатическую боль, особенно и предпочтительно в условиях, характеризующихся периферическим нейрогенным воспалением от низкой до умеренной степени, таких как мелковолоконная нейропатия, диабетическая нейропатия, хроническая идиопатическая аксональная полинейропатия, постгерпетическая невралгия, тригеминальная невралгия, полинейропатия, вызванная химиотерапией, травматические нейропатии, компрессионные нейропатии и инфекционные нейропатии в состоянии ремиссии, в соответствии с настоящим изобретением.
EA201991341A 2016-12-06 2017-12-06 Фенитоин для местного применения для лечения периферической нейропатической боли EA201991341A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2017931 2016-12-06
PCT/NL2017/050814 WO2018106107A1 (en) 2016-12-06 2017-12-06 Topical phenytoin for use in the treatment of peripheral neuropathic pain

Publications (1)

Publication Number Publication Date
EA201991341A1 true EA201991341A1 (ru) 2019-12-30

Family

ID=57796933

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991341A EA201991341A1 (ru) 2016-12-06 2017-12-06 Фенитоин для местного применения для лечения периферической нейропатической боли

Country Status (17)

Country Link
US (1) US11285099B2 (ru)
EP (1) EP3551166A1 (ru)
JP (1) JP7264813B2 (ru)
CN (1) CN110248644A (ru)
AU (1) AU2017371467B2 (ru)
BR (1) BR112019011743A2 (ru)
CA (1) CA3046055A1 (ru)
CL (1) CL2019001550A1 (ru)
DO (1) DOP2019000156A (ru)
EA (1) EA201991341A1 (ru)
IL (1) IL267114B1 (ru)
MA (1) MA51978A (ru)
MX (1) MX2019006640A (ru)
PH (1) PH12019550093A1 (ru)
UA (1) UA125040C2 (ru)
WO (1) WO2018106107A1 (ru)
ZA (1) ZA201906473B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021043673A1 (en) 2019-09-02 2021-03-11 Syddansk Universitet P-gp inducers as protectors against chemotherapy-induced side effects, such as peripheral neuropathy (cipn) and hair loss
CN114681340A (zh) * 2022-04-13 2022-07-01 肌赋萃生物科技(上海)有限公司 一种含有脂质包裹稳定技术的脂质屏障修复护肤品及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571521A (en) 1984-01-16 1996-11-05 Lasker; Sigmund E. Composition containing silver ammonium phenytoin complex and a phenytoin and use of said composition
JPH0772190B2 (ja) * 1985-02-26 1995-08-02 エーザイ株式会社 ヒダントイン誘導体
JP3031973B2 (ja) 1990-08-16 2000-04-10 富士レビオ株式会社 フェニトイン誘導体
US6113921A (en) * 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
CN1046199C (zh) * 1994-12-13 1999-11-10 凌吉安 复方消炎止痛霜剂
WO1998007447A1 (en) 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
WO2001000191A2 (en) * 1999-06-23 2001-01-04 Warner-Lambert Company Use of fosphenytion for the treatment of acute neuropathic pain
US20040191276A1 (en) 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
RU2262922C2 (ru) * 2001-05-15 2005-10-27 Уорнер-Ламберт Компани Ллс Способ прессования для получения лекарственной формы фенитоина натрия
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
JP2008508339A (ja) 2004-08-03 2008-03-21 ロイヤル カレッジ オブ サージャンズ イン アイルランド フェニトイン製剤および創傷治癒におけるその使用
US20060034910A1 (en) * 2004-08-09 2006-02-16 Sanjay Patel Pharmaceutical composition for extended release of phenytoin sodium
CN101069692B (zh) * 2006-05-08 2011-04-20 范敏华 含积雪草总甙的药物制剂及其制备方法
US20100029618A1 (en) 2006-12-22 2010-02-04 Gil Daniel W Alpha-2 receptor pan agonist and anticonvulsant compositions for treating chronic pain
CA2721341C (en) * 2008-04-14 2016-10-11 National University Corporation Nagoya University Therapeutic agent for neurogenic pain
JP2011526889A (ja) 2008-06-30 2011-10-20 アフギン ファーマ，エルエルシー 局所局部的神経作用療法
CN102223791A (zh) 2008-09-27 2011-10-19 塔阿克斯有限公司 用于神经病变治疗的局部用制剂
KR101271219B1 (ko) * 2011-01-27 2013-06-07 광주과학기술원 신규한 하이단토인 유도체 및 이의 용도
US8920831B2 (en) 2011-06-20 2014-12-30 Hisamitsu Pharmaceutical Co., Inc. Lidocaine-containing hydrogel patch
US20130184351A1 (en) 2011-12-21 2013-07-18 Jar Laboratories Lidocaine patch and methods of use thereof
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US20160303203A1 (en) * 2013-12-09 2016-10-20 Keshav Malshe Compositions and methods for the treatment of wounds
CN106075556A (zh) 2016-06-02 2016-11-09 四川奎星医用高分子制品有限责任公司 含有促进伤口愈合药物的医用复合壳聚糖凝胶

Also Published As

Publication number Publication date
CL2019001550A1 (es) 2020-02-28
JP2020500915A (ja) 2020-01-16
EP3551166A1 (en) 2019-10-16
WO2018106107A1 (en) 2018-06-14
UA125040C2 (uk) 2021-12-29
ZA201906473B (en) 2020-07-29
US11285099B2 (en) 2022-03-29
IL267114A (en) 2019-08-29
CA3046055A1 (en) 2018-06-14
MX2019006640A (es) 2019-08-01
PH12019550093A1 (en) 2020-02-10
AU2017371467B2 (en) 2023-06-01
US20200276106A1 (en) 2020-09-03
BR112019011743A2 (pt) 2019-10-22
MA51978A (fr) 2021-01-20
AU2017371467A1 (en) 2019-07-25
CN110248644A (zh) 2019-09-17
DOP2019000156A (es) 2020-07-15
IL267114B1 (en) 2024-04-01
JP7264813B2 (ja) 2023-04-25

Similar Documents

Publication Publication Date Title
EA201791261A1 (ru) 1,3-тиазол-2-ил замещенные бензамиды
PH12017501473A1 (en) Novel proteins specific for pyoverdine and pyochelin
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
EA201891336A1 (ru) Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
EA201591327A1 (ru) Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
EA201890842A1 (ru) Комбинация гликозаминогликанов и антацидного агента и содержащие их композиции
NO20180002A1 (en) Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
MX340985B (es) Compuestos de n-heteroarilo.
CL2007002862A1 (es) Uso del factor de crecimiento epidermico (egf) para tratar neuropatia sensitivo-motora, dolorosa y manifestaciones de neuritis isquemicas; composicion farmaceutica que comprende egf; y uso de la composicion antes dicha.
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
EA201791814A1 (ru) Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления
EA201991341A1 (ru) Фенитоин для местного применения для лечения периферической нейропатической боли
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
EA202091561A1 (ru) Фармацевтическая композиция, содержащая фармацевтически приемлемую кислотно-аддитивную соль леналидомида
EA201990162A1 (ru) Фармацевтические композиции
EA201270547A1 (ru) Фармацевтическая композиция
IN2013MU02370A (ru)
MX2016013108A (es) Nueva composicion para el tratamiento de la tricomoniasis.
EA201691206A1 (ru) Ноотропное средство "пантокальцин" в жидкой форме